Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 7/20 | 0.47 |
| ▸ | FYN | P06241 | 4/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | FLT4 | P35916 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13810667 | 0.84 | KDR (0.53) | METCYP17A1CYP11B1CYP11B2KDR | |
| SCHEMBL13810663 | 0.82 | MET (0.68) | MET | |
| SCHEMBL13810670 | 0.79 | MET (0.48) | METFYNCYP11B1CYP11B2KDR | |
| SCHEMBL4312306 | 0.71 | CYP17A1 (0.66) | METFYNCYP17A1CYP11B1CYP11B2 | |
| SCHEMBL13810662 | 0.66 | KDR (0.49) | METCYP11B1CYP11B2KDRMAOB | |
| SCHEMBL7618973 | 0.64 | KDR (0.76) | KDRFLT1FLT4 | |
| SCHEMBL7448864 | 0.64 | CYP2A6 (0.58) | FYNCYP17A1CYP11B1CYP11B2CYP2A6 | |
| SCHEMBL649500 | 0.64 | CYP2A6 (0.58) | FYNCYP17A1CYP11B1CYP11B2CYP2A6 | |
| SCHEMBL5652167 | 0.63 | ESR1 (0.61) | METCYP17A1CYP11B1CYP11B2 | |
| SCHEMBL28764321 | 0.62 | CYP2A6 (0.56) | FYNCYP17A1CYP11B1CYP11B2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156617-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156617-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, MET | MET 3/4885FYN 39/4885CYP17A1 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.